This forum is for the discussion of anything to do with Prostate Cancer. There are only four rules:
No fundraisers, no commercials (although it is OK to recommend choices of treatment or medical people based on your personal research; invitations to participate in third-party surveys are also acceptable, provided there is no compensation to YANA);
No harvesting e-mail addresses for Spam;
No insults or flaming - be polite and respectful at all times and understand that there may be a variety of points of view, all of which may have some validity;
Opinions are OK, but please provide as much factual evidence as possible for any assertions that you are making
Failure to abide by these simple rules will result in the immediate and permanent suspension of your posting privileges.
Since this is an International Forum, please specify your location in your post.
Al,
I suspect you haven't heard anything because pembrolizumab is not a common treatment (yet) for PCa.
This immunotherapy -- more commonly known as Keytruda-- is more commonly used on lung cancer if chemo fails. The trouble I see with Keytruda is that it costs about $150,000 for a year's treatment and it seems to be effective in less than 20% of the time. I read somewhere that in PCa it was less than 10%. I think in 10-20 years immunotherapy will be more effective and less costly, but for now it just isn't.